Clinical impact and evolution of mitral regurgitation following transcatheter aortic valve replacement : a meta-analysis

Authors: Nombela-Franco, Luis; Eltchaninoff, Hélène; Zahn, Ralf; Testa, Luca; Leon, Martin B.; Trillo-Nouche, Ramiro; D'Onofrio, Augusto; Smith, Craig R.; Webb, John G. (John Graydon); Bleiziffer, Sabine; De Chiara, Benedetta; Gilard, Martine; Tamburino, Corrado; Bedogni, Francesco; Barbanti, Marco; Salizzoni, Stefano; García del Blanco, Bruno; Sabaté, Manel; Moreo, Antonella; Pérez, Cristina Fernández; Ribeiro, Henrique BarbosaAmat Santos, Ignacio J.Urena Alcazar, MarinaAllende, Ricardo; García, Eulogio; Macaya, Carlos; Dumont, ÉricPibarot, PhilippeRodés-Cabau, Josep
Abstract: Objectives: Mitral regurgitation (MR) is a common entity in patients with aortic stenosis undergoing transcatheter aortic valve replacement (TAVR), but its influence on outcomes remains controversial. The purpose of this metaanalysis was to assess the clinical impact of and changes in significant (moderate–severe) MR in patients undergoing TAVR, overall and according to valve design (selfexpandable (SEV) vs balloon-expandable (BEV)). Methods: All national registries and randomised trials were pooled using meta-analytical guidelines to establish the impact of moderate–severe MR on mortality after TAVR. Studies reporting changes in MR after TAVR on an individual level were electronically searched and used for the analysis. Results: Eight studies including 8015 patients (SEV: 3474 patients; BEV: 4492 patients) were included in the analysis. The overall 30-day and 1-year mortality was increased in patients with significant MR (OR 1.49, 95% CI 1.16 to 1.92; HR 1.32, 95% CI 1.12 to 1.55, respectively), but a significant heterogeneity across studies was observed (p<0.05). The impact of MR on mortality was not different between SEV and BEV in meta-regression analysis for 30- day (p=0.360) and 1-year (p=0.388) mortality. Changes in MR over time were evaluated in nine studies including 1278 patients. Moderate–severe MR (SEV: 326 patients; BEV: 192 patients) improved in 50.5% of the patients at a median follow-up of 180 (30–360) days after TAVR, and the degree of improvement was greater in patients who had received a BEV (66.7% vs 40.8% in the SEV group, p=0.001). Conclusions: Concomitant moderate–severe MR was associated with increased early and late mortality following TAVR. A significant improvement in MR severity was detected in half of the patients following TAVR, and the degree of improvement was greater in those patients who had received a BEV.
Document Type: Article de recherche
Issue Date: 9 June 2015
Open Access Date: Restricted access
Document version: VoR
This document was published in: Heart, Vol. 101 (17), 1395-1405 (2015)
British Cardiac Society
Alternative version: 10.1136/heartjnl-2014-307120
Collection:Articles publiés dans des revues avec comité de lecture

Files in this item:
1.98 MBAdobe PDF    Request a copy
All documents in CorpusUL are protected by Copyright Act of Canada.